#Norway #Oslo #Navamedic ASA #Extraordinary General Meeting #Kathrine G. Andreassen

Navamedic ASA Concludes Extraordinary General Meeting

On July 14, 2025, at 13:00 CET, Navamedic ASA conducted its Extraordinary General Meeting (EGM) in Oslo, Norway. This significant event reconfirmed the company's governance, with all agenda items receiving unanimous approval based on the proposals made by the board of directors.

In light of recent developments in the healthcare sector, the EGM was particularly important for the strategic direction of Navamedic. The board presented detailed insights into upcoming products and initiatives aimed at enhancing healthcare solutions. These proposals included updates on product launches, strategic partnerships, and market expansion strategies.

Kathrine G. Andreassen, CEO of Navamedic, expressed her satisfaction with the meeting's outcomes. "The approval of all agenda items reflects our shareholders' trust in our vision and plans for the future of Navamedic. We remain committed to driving innovation and improving access to essential healthcare products," she stated after the meeting.

Additionally, shareholders were able to review and discuss the attached minutes from the meeting, which encompass all decisions taken. These minutes will also be published on the company’s official website, ensuring transparency and accessibility for stakeholders.

Moreover, both Kathrine G. Andreassen and CFO Lars Hjarrand were present at the meeting, ready to address any questions and concerns from attendees. This open communication channel is a testament to Navamedic's commitment to shareholder engagement and corporate governance.

The decisions made during the EGM are crucial as Navamedic forges ahead in a competitive landscape. With a solid plan and the backing of its shareholders, the company is poised for growth and success in the upcoming quarters.

For those interested in following Navamedic’s journey, the published minutes and further updates will be continuously available on their website, enhancing stakeholders' ability to track the company’s progress.

Should you need further information or have inquiries, Navamedic encourages direct contact with their CEO or CFO, who are readily accessible for communications. Their commitment to transparency shines through as they welcome feedback from their investor community.

This EGM marks yet another step in Navamedic's strategic path, solidifying their place within the pharmaceutical sector. As they move forward, the focus will remain on delivering value to shareholders while continuing to meet the healthcare needs of patients worldwide. This meeting not only legitimizes past decisions but also sets a clear roadmap for future endeavors.

Overall, the successful execution of the Extraordinary General Meeting today affirms the trust and collaboration among Navamedic's leadership, board, and shareholders. Looking ahead, the company aims to leverage its strengths and further innovate in ways that drive advancement in the healthcare industry, ultimately benefiting patients and providers alike.

For additional details and to read the minutes from the EGM, visit www.navamedic.com when they become available.